Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 162 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. The company is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Follow-Up Questions
Rigel Pharmaceuticals Inc (RIGL)의 PER은 얼마입니까?
Rigel Pharmaceuticals Inc의 PER은 35.6182입니다
Rigel Pharmaceuticals Inc의 CEO는 누구입니까?
Mr. Raul Rodriguez은 2000부터 회사에 합류한 Rigel Pharmaceuticals Inc의 President입니다.
RIGL 주식의 가격 성능은 어떻습니까?
RIGL의 현재 가격은 $27.94이며, 전 거래일에 decreased 0% 하였습니다.
Rigel Pharmaceuticals Inc의 주요 사업 주제나 업종은 무엇입니까?
Rigel Pharmaceuticals Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Rigel Pharmaceuticals Inc의 시가총액은 얼마입니까?
Rigel Pharmaceuticals Inc의 현재 시가총액은 $501.2M입니다
Rigel Pharmaceuticals Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 8명의 분석가가 Rigel Pharmaceuticals Inc에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 4명의 매수, 5명의 보유, 0명의 매도, 그리고 3명의 강력한 매도를 포함합니다
